New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
06:33 EDTAVEOAveo, Astellas announce initiation of patient enrollment in tivozanib trial
AVEO Oncology and Astellas Pharma announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating the efficacy of tivozanib, an investigational drug, in combination with paclitaxel compared to placebo in combination with paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer who have received no prior systemic therapy for advanced or metastatic breast cancer. Triple negative breast cancer was selected for tivozanib clinical evaluation because of high unmet need and insights gained from AVEO's Human Response PlatformTM indicating that these tumors are enriched for a signature of VEGF pathway deregulation similar to that seen in renal cell carcinoma.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:52 EDTAVEOAveo Pharmaceuticals shares recommended by Agora Financial
Agora Financial named Aveo Pharmaceuticals a new buy recommendation with a $57 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use